These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

259 related items for PubMed ID: 15217455

  • 1. Interleukin-2 blocks the antitumour activity caused by depletion of CD25 cells in a murine renal adenocarcinoma model.
    Takeuchi T, Konno-Takahashi N, Kasuya Y, Ogushi T, Nishimatsu H, Kitamura T.
    BJU Int; 2004 Jul; 94(1):171-6. PubMed ID: 15217455
    [Abstract] [Full Text] [Related]

  • 2. Neutralization of interleukin-2 retards the growth of mouse renal cancer.
    Fukuhara H, Matsumoto A, Kitamura T, Takeuchi T.
    BJU Int; 2006 Jun; 97(6):1314-21. PubMed ID: 16686731
    [Abstract] [Full Text] [Related]

  • 3. Trafficking of 'immune' CD4(+)/CD8(+)T-lymphocytes into the RENCA tumour microcirculation in vivo in mice.
    Ali SA, Rees RC, Anderson DQ, Reed MW, Goepel JR, Brown NJ.
    Br J Cancer; 2000 Oct; 83(8):1061-8. PubMed ID: 10993655
    [Abstract] [Full Text] [Related]

  • 4. Complete regression of experimental solid tumors by combination LEC/chTNT-3 immunotherapy and CD25(+) T-cell depletion.
    Li J, Hu P, Khawli LA, Epstein AL.
    Cancer Res; 2003 Dec 01; 63(23):8384-92. PubMed ID: 14679000
    [Abstract] [Full Text] [Related]

  • 5. In vivo elimination of CD25+ regulatory T cells leads to tumor rejection of B16F10 melanoma, when combined with interleukin-12 gene transfer.
    Nagai H, Horikawa T, Hara I, Fukunaga A, Oniki S, Oka M, Nishigori C, Ichihashi M.
    Exp Dermatol; 2004 Oct 01; 13(10):613-20. PubMed ID: 15447721
    [Abstract] [Full Text] [Related]

  • 6. Anti-tumour activity of heat-shock protein 60-recognizing CD4+ T cells against syngeneic murine renal cell carcinoma.
    Eto M, Harada M, Tatsugami K, Harano M, Koga H, Matsuzaki G, Naito S.
    BJU Int; 2005 Feb 01; 95(3):421-4. PubMed ID: 15679807
    [Abstract] [Full Text] [Related]

  • 7. Synergistic in vivo antitumor effect of the histone deacetylase inhibitor MS-275 in combination with interleukin 2 in a murine model of renal cell carcinoma.
    Kato Y, Yoshimura K, Shin T, Verheul H, Hammers H, Sanni TB, Salumbides BC, Van Erp K, Schulick R, Pili R.
    Clin Cancer Res; 2007 Aug 01; 13(15 Pt 1):4538-46. PubMed ID: 17671140
    [Abstract] [Full Text] [Related]

  • 8. Interleukin-21 activates cytotoxic T lymphocytes and natural killer cells to generate antitumor response in mouse renal cell carcinoma.
    Kumano M, Hara I, Furukawa J, Oniki S, Nagai H, Miyake H, Fujisawa M.
    J Urol; 2007 Oct 01; 178(4 Pt 1):1504-9. PubMed ID: 17707061
    [Abstract] [Full Text] [Related]

  • 9. Inhibition of murine renal carcinoma pulmonary metastases by systemic administration of interferon gamma: mechanism of action and potential for combination with interleukin 4.
    Hillman GG, Younes E, Visscher D, Hamzavi F, Kim S, Lam JS, Montecillo EJ, Ali E, Pontes JE, Puri RK, Haas GP.
    Clin Cancer Res; 1997 Oct 01; 3(10):1799-806. PubMed ID: 9815566
    [Abstract] [Full Text] [Related]

  • 10. Immunotherapy of established tumors in mice by intratumoral injection of interleukin-2 plasmid DNA: induction of CD8+ T-cell immunity.
    Saffran DC, Horton HM, Yankauckas MA, Anderson D, Barnhart KM, Abai AM, Hobart P, Manthorpe M, Norman JA, Parker SE.
    Cancer Gene Ther; 1998 Oct 01; 5(5):321-30. PubMed ID: 9824052
    [Abstract] [Full Text] [Related]

  • 11. Effectiveness of cancer vaccine therapy using cells transduced with the interleukin-12 gene combined with systemic interleukin-18 administration.
    Hara I, Nagai H, Miyake H, Yamanaka K, Hara S, Micallef MJ, Kurimoto M, Gohji K, Arakawa S, Ichihashi M, Kamidono S.
    Cancer Gene Ther; 2000 Jan 01; 7(1):83-90. PubMed ID: 10678360
    [Abstract] [Full Text] [Related]

  • 12. Antitumor efficacy of recombinant human interleukin-2 combined with sorafenib against mouse renal cell carcinoma.
    Iguchi M, Matsumoto M, Hojo K, Wada T, Matsuo Y, Arimura A, Abe K.
    Jpn J Clin Oncol; 2009 May 01; 39(5):303-9. PubMed ID: 19336449
    [Abstract] [Full Text] [Related]

  • 13. Depletion of CD25+ regulatory cells results in suppression of melanoma growth and induction of autoreactivity in mice.
    Jones E, Dahm-Vicker M, Simon AK, Green A, Powrie F, Cerundolo V, Gallimore A.
    Cancer Immun; 2002 Feb 22; 2():1. PubMed ID: 12747746
    [Abstract] [Full Text] [Related]

  • 14. Combinations of tumor-specific CD8+ CTLs and anti-CD25 mAb provide improved immunotherapy.
    Ohmura Y, Yoshikawa K, Saga S, Ueda R, Kazaoka Y, Yamada S.
    Oncol Rep; 2008 May 22; 19(5):1265-70. PubMed ID: 18425386
    [Abstract] [Full Text] [Related]

  • 15. Administration of recombinant human IL-7 to mice alters the composition of B-lineage cells and T cell subsets, enhances T cell function, and induces regression of established metastases.
    Komschlies KL, Gregorio TA, Gruys ME, Back TC, Faltynek CR, Wiltrout RH.
    J Immunol; 1994 Jun 15; 152(12):5776-84. PubMed ID: 8207207
    [Abstract] [Full Text] [Related]

  • 16. Gene-modified tumor vaccine secreting a designer cytokine Hyper-Interleukin-6 is an effective therapy in mice bearing orthotopic renal cell cancer.
    Wysocki PJ, Kazimierczak U, Suchorska W, Kotlarski M, Malicki J, Mackiewicz A.
    Cancer Gene Ther; 2010 Jul 15; 17(7):465-75. PubMed ID: 20168352
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Potentiation of a dendritic cell vaccine for murine renal cell carcinoma by CpG oligonucleotides.
    Chagnon F, Tanguay S, Ozdal OL, Guan M, Ozen ZZ, Ripeau JS, Chevrette M, Elhilali MM, Thompson-Snipes LA.
    Clin Cancer Res; 2005 Feb 01; 11(3):1302-11. PubMed ID: 15709202
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.